Genmab — Februar 2021
-
Danske Bank opjusterer, 2675 (2600). "Key items at the FY2020 results reflected the Halozyme royalties of which Janssen withheld a larger share than we anticipated. Genmab sees possibilities of bringing one new drug candidate into late-stage clinical development. Looking at the pipeline, we believe this reflects potential pivotal testing of GEN1046. We upgrade to Buy and adjust our 12M target price to DKK2,675."
-
Genmab-CFO: Det kan bidrage med en halv milliard i 2021 (Kesimpta og Tepezza.) https://www.euroinvestor.dk/nyheder/genmab-cfo-det-kan-bidrage-med-en-halv-milliard-i-2021
-
Genmab A/S (GMAB) Q4 2020 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2021/02/23/genmab-as-gmab-q4-2020-earnings-call-transcript/
-
Solsen 8:47. Fra ritzau: Ifølge topchef i Genmab, Jan van de Winkel, er der indtil flere studier undervejs i en lang række lymfekræftformer baseret på B-celle defekter.
- Vi kan få data i år, som potentielt kan give os mulighed for at ansøge om markedsføringstilladelse næste år.
-
Børen - "Genmab-kursmål sænkes på stribe", det må således være den halve sandhed hvis den står 2-2
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind